Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study (Q43468587)

23 November 2017

Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study (English)

1 reference

23 November 2017

1 reference

Pierre Delanaye

1

1 reference

23 November 2017

Laurent Weekers

2

1 reference

23 November 2017

Xavier Warling

3

1 reference

23 November 2017

Martial Moonen

4

1 reference

23 November 2017

Nicole Smelten

5

1 reference

23 November 2017

Laurent Médart

6

1 reference

23 November 2017

Jean-Marie Krzesinski

7

1 reference

23 November 2017

Etienne Cavalier

8

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

Nephrology Dialysis Transplantation

23 November 2017

1 reference

23 November 2017

28

1 reference

23 November 2017

1779-1786

1 reference

23 November 2017

7

1 reference

Vitamin D: current status and perspectives

23 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Evidence for extrarenal production of 1 alpha ,25-dihydroxyvitamin D in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Vitamin D therapy in chronic kidney disease and end stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Clinical measures identify vitamin D deficiency in dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Vitamin D affects survival independently of vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Pitfalls of measuring total blood calcium in patients with CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Vitamin D receptor activators can protect against vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

Vitamin D deficiency, mortality, and hospitalization in hemodialysis patients with or without protein-energy wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT001

21 January 2018

Identifiers

DOI

10.1093/NDT/GFT001

1 reference

23 November 2017

1 reference